Revenue (Quarterly) Chart

View Revenue (Quarterly) for GRFS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
March 31, 2026 1.989B
December 31, 2025 2.307B
September 30, 2025 2.180B
June 30, 2025 2.144B
March 31, 2025 1.879B
December 31, 2024 2.108B
September 30, 2024 1.970B
June 30, 2024 1.957B
March 31, 2024 1.764B
December 31, 2023 1.903B
September 30, 2023 1.738B
June 30, 2023 1.810B
March 31, 2023 1.655B
March 31, 2021 1.427B
December 31, 2020 1.561B
September 30, 2020 1.582B
June 30, 2020 1.524B
March 31, 2020 1.425B
December 31, 2019 1.507B
September 30, 2019 1.461B
June 30, 2019 1.423B
March 31, 2019 1.313B
December 31, 2018 1.395B
September 30, 2018 1.330B
June 30, 2018 1.307B
Date Value
March 31, 2018 1.257B
December 31, 2017 1.257B
September 30, 2017 1.243B
June 30, 2017 1.245B
March 31, 2017 1.132B
December 31, 2016 1.183B
September 30, 2016 1.116B
June 30, 2016 1.121B
March 31, 2016 1.057B
December 31, 2015 1.163B
September 30, 2015 1.079B
June 30, 2015 1.098B
March 31, 2015 1.021B
December 31, 2014 1.146B
September 30, 2014 1.096B
June 30, 2014 1.115B
March 31, 2014 1.093B
December 31, 2013 946.31M
September 30, 2013 881.55M
June 30, 2013 910.24M
March 31, 2013 902.68M
December 31, 2012 857.80M
September 30, 2012 803.64M
June 30, 2012 833.25M
March 31, 2012 873.92M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Amarin Corp. Plc 45.06M
Cellectis SA 5.798M
Autolus Therapeutics Plc 26.17M
Akari Therapeutics Plc 0.00
Evaxion AS 0.00